Metraipolis › archive › dc_34ffe9df7564

AB-5'F-BUTINACA — Wikipedia (en)

Source
Wikipedia (en)
Original
https://en.wikipedia.org/wiki/AB-5%27F-BUTINACA
License (as archived)
CC-BY-SA-4.0
Archived
2026-11-06T23:22:19.256Z
SHA-256 of the archived text
d0d5e961f8d0c0d05b054d004215808d78fb63367e03f46fb1141a6ecf337fc3
Stable URL of this page
https://metraipolis.com/documento/dc_34ffe9df7564

How to cite

AB-5'F-BUTINACA — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/AB-5%27F-BUTINACA (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_34ffe9df7564 (Metraipolis archive dc_34ffe9df7564, sha256 d0d5e961f8d0c0d05b054d004215808d78fb63367e03f46fb1141a6ecf337fc3)
BibTeX
@misc{dc34ffe9df7564,
  title = {AB-5'F-BUTINACA — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/AB-5%27F-BUTINACA},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_34ffe9df7564; sha256 d0d5e961f8d0c0d05b054d004215808d78fb63367e03f46fb1141a6ecf337fc3},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/AB-5%27F-BUTINACA. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

AB-5'F-BUTINACA is a synthetic cannabinoid of the indazole family. It is a potent full agonist of the cannabinoid CB1 receptor, with an EC50Tooltip half-maximal effective concentration of 18.7 nM and an EmaxTooltip maximal efficacy relative to JWH-018 of 107%. In addition to its cannabinoid CB1 receptor agonism, AB-5'F-BUTINACA is also a very-low-potency serotonin 5-HT2A receptor partial agonist, with an EC50 of greater than 10,000 nM and an Emax relative to LSD of 67.3%. The drug was the most efficacious serotonin 5-HT2A receptor agonist of a series of assessed synthetic cannabinoids. However, due to its very low potency, this action may not be pharmacologically relevant. AB-5'F-BUTINACA produces effects in rodents including neurological changes, sensorimotor alterations, analgesia, hypothermia, bradypnea, hypolocomotion, convulsions, and hyperreflexia. These effects can be variably reversed by the selective cannabinoid CB1 receptor antagonist NESS-0327 and by the selective serotonin 5-HT2A receptor antagonist volinanserin (MDL-100907). The drug did not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It is said to be unclear whether the serotonin 5-HT2A receptor involvement in AB-5'F-BUTINACA's effects is due to direct interaction with this receptor or mere endocannabinoid system modulation of the serotonin system. The chemical synthesis of AB-5'F-BUTINACA has been described. AB-5'F-BUTINACA was first described in the scientific literature by 2025.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico).
Fonte: Wikipedia in inglese, voce «AB-5'F-BUTINACA» — https://en.wikipedia.org/wiki/AB-5%27F-BUTINACA
Wikidata Q139916098: «pharmaceutical compound» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q139916098
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/AB-5%27F-BUTINACA?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1382838092, consultata il 2026-11-06T23:18:45.573Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 3cdca1c67773bfe6357b7df27bc0ad55eecf387a03654a0b0d59aa6e771725f0